Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice

<p>Abstract</p> <p>Background</p> <p>Obesity and related metabolic abnormalities, including inflammation and lipid accumulation in the liver, play a role in liver carcinogenesis. Adipocytokine imbalances, such as decreased serum adiponectin levels, are also involved in...

Full description

Bibliographic Details
Main Authors: Kochi Takahiro, Ohno Tomohiko, Baba Atsushi, Terakura Daishi, Kubota Masaya, Sakai Hiroyasu, Yasuda Yoichi, Shimizu Masahito, Tsurumi Hisashi, Tanaka Takuji, Moriwaki Hisataka
Format: Article
Language:English
Published: BMC 2011-06-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/281
id doaj-156560f6ea5f4cc6b78cddd85e6dac07
record_format Article
spelling doaj-156560f6ea5f4cc6b78cddd85e6dac072020-11-25T00:18:55ZengBMCBMC Cancer1471-24072011-06-0111128110.1186/1471-2407-11-281Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese miceKochi TakahiroOhno TomohikoBaba AtsushiTerakura DaishiKubota MasayaSakai HiroyasuYasuda YoichiShimizu MasahitoTsurumi HisashiTanaka TakujiMoriwaki Hisataka<p>Abstract</p> <p>Background</p> <p>Obesity and related metabolic abnormalities, including inflammation and lipid accumulation in the liver, play a role in liver carcinogenesis. Adipocytokine imbalances, such as decreased serum adiponectin levels, are also involved in obesity-related liver tumorigenesis. In the present study, we examined the effects of pitavastatin - a drug used for the treatment of hyperlipidemia - on the development of diethylnitrosamine (DEN)-induced liver preneoplastic lesions in C57BL/KsJ-<it>db/db </it>(<it>db/db</it>) obese mice.</p> <p>Methods</p> <p>Male <it>db/db </it>mice were administered tap water containing 40 ppm DEN for 2 weeks and were subsequently fed a diet containing 1 ppm or 10 ppm pitavastatin for 14 weeks.</p> <p>Results</p> <p>At sacrifice, feeding with 10 ppm pitavastatin significantly inhibited the development of hepatic premalignant lesions, foci of cellular alteration, as compared to that in the untreated group by inducing apoptosis, but inhibiting cell proliferation. Pitavastatin improved liver steatosis and activated the AMPK-α protein in the liver. It also decreased free fatty acid and aminotransferases levels, while increasing adiponectin levels in the serum. The serum levels of tumor necrosis factor (TNF)-α and the expression of <it>TNF-α </it>and <it>interleukin-6 </it>mRNAs in the liver were decreased by pitavastatin treatment, suggesting attenuation of the chronic inflammation induced by excess fat deposition.</p> <p>Conclusions</p> <p>Pitavastatin is effective in inhibiting the early phase of obesity-related liver tumorigenesis and, therefore, may be useful in the chemoprevention of liver cancer in obese individuals.</p> http://www.biomedcentral.com/1471-2407/11/281
collection DOAJ
language English
format Article
sources DOAJ
author Kochi Takahiro
Ohno Tomohiko
Baba Atsushi
Terakura Daishi
Kubota Masaya
Sakai Hiroyasu
Yasuda Yoichi
Shimizu Masahito
Tsurumi Hisashi
Tanaka Takuji
Moriwaki Hisataka
spellingShingle Kochi Takahiro
Ohno Tomohiko
Baba Atsushi
Terakura Daishi
Kubota Masaya
Sakai Hiroyasu
Yasuda Yoichi
Shimizu Masahito
Tsurumi Hisashi
Tanaka Takuji
Moriwaki Hisataka
Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice
BMC Cancer
author_facet Kochi Takahiro
Ohno Tomohiko
Baba Atsushi
Terakura Daishi
Kubota Masaya
Sakai Hiroyasu
Yasuda Yoichi
Shimizu Masahito
Tsurumi Hisashi
Tanaka Takuji
Moriwaki Hisataka
author_sort Kochi Takahiro
title Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice
title_short Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice
title_full Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice
title_fullStr Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice
title_full_unstemmed Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-<it>db/db </it>obese mice
title_sort pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male c57bl/ksj-<it>db/db </it>obese mice
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2011-06-01
description <p>Abstract</p> <p>Background</p> <p>Obesity and related metabolic abnormalities, including inflammation and lipid accumulation in the liver, play a role in liver carcinogenesis. Adipocytokine imbalances, such as decreased serum adiponectin levels, are also involved in obesity-related liver tumorigenesis. In the present study, we examined the effects of pitavastatin - a drug used for the treatment of hyperlipidemia - on the development of diethylnitrosamine (DEN)-induced liver preneoplastic lesions in C57BL/KsJ-<it>db/db </it>(<it>db/db</it>) obese mice.</p> <p>Methods</p> <p>Male <it>db/db </it>mice were administered tap water containing 40 ppm DEN for 2 weeks and were subsequently fed a diet containing 1 ppm or 10 ppm pitavastatin for 14 weeks.</p> <p>Results</p> <p>At sacrifice, feeding with 10 ppm pitavastatin significantly inhibited the development of hepatic premalignant lesions, foci of cellular alteration, as compared to that in the untreated group by inducing apoptosis, but inhibiting cell proliferation. Pitavastatin improved liver steatosis and activated the AMPK-α protein in the liver. It also decreased free fatty acid and aminotransferases levels, while increasing adiponectin levels in the serum. The serum levels of tumor necrosis factor (TNF)-α and the expression of <it>TNF-α </it>and <it>interleukin-6 </it>mRNAs in the liver were decreased by pitavastatin treatment, suggesting attenuation of the chronic inflammation induced by excess fat deposition.</p> <p>Conclusions</p> <p>Pitavastatin is effective in inhibiting the early phase of obesity-related liver tumorigenesis and, therefore, may be useful in the chemoprevention of liver cancer in obese individuals.</p>
url http://www.biomedcentral.com/1471-2407/11/281
work_keys_str_mv AT kochitakahiro pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT ohnotomohiko pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT babaatsushi pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT terakuradaishi pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT kubotamasaya pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT sakaihiroyasu pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT yasudayoichi pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT shimizumasahito pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT tsurumihisashi pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT tanakatakuji pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
AT moriwakihisataka pitavastatinsuppressesdiethylnitrosamineinducedliverpreneoplasmsinmalec57blksjitdbdbitobesemice
_version_ 1725374378419421184